Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Sema4 Holdings Corp. Warrant SMFRW

Sema4 Holdings Corp is a patient-centered health intelligence company dedicated to advancing healthcare through data-driven insights. It is transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories.

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (NDAQ:SMFRW)

Fundamentals Snapshot (NDAQ:SMFRW)

Current News (NDAQ:SMFRW)

Sema4 Reports Third Quarter 2022 Financial Results and New Strategic Direction

GlobeNewswire 13 days ago

FINAL DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Sema4 Holdings Corp. with Losses of $100,000 to Contact the Firm

Accesswire November 7, 2022

24-Hour Deadline Alert: The Schall Law Firm Encourages Investors in Sema4 Holdings Corp. with Losses to Contact the Firm

Accesswire November 6, 2022

3-Day Deadline Alert: The Schall Law Firm Encourages Investors in Sema4 Holdings Corp. with Losses to Contact the Firm

Accesswire November 4, 2022

Sema4 to Report Third Quarter 2022 Financial Results on Monday, November 14th, 2022

GlobeNewswire November 4, 2022

4-Day Deadline Alert: The Schall Law Firm Encourages Investors in Sema4 Holdings Corp. with Losses to Contact the Firm

Accesswire November 3, 2022

5-Day Deadline Alert: The Schall Law Firm Encourages Investors in Sema4 Holdings Corp. with Losses to Contact the Firm

Accesswire November 2, 2022

Sema4|GeneDx Commends New Evidence-Based Guidelines from the National Society of Genetic Counselors Recommending Exome Sequencing as a First-Tier Genetic Test for Unexplained Epilepsies

GlobeNewswire October 31, 2022

Sema4|GeneDx Announces Results from Phase 1 of SeqFirst Study, Demonstrating Broad Utility of Rapid Whole Genome Sequencing for Critically Ill Newborns

GlobeNewswire October 27, 2022

Opinion & Analysis (NDAQ:SMFRW)

No current opinion is available.

Bullboard Posts (NDAQ:SMFRW)